Sanofi may win U.S. approval of $3 billion eczema drug by March
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
- JPMorgan (JPM) Reports Q4 EPS of $1.71
French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
(Reuters) - French drugmaker Sanofi
Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition.
The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis (AD), a skin inflammation also known as atopic eczema, and set a target decision date of March 29.
Dupilumab, an injectable antibody drug, is seen by investors as perhaps Sanofi's most promising pipeline medicine, since it has produced promising clinical results and could be first systemic therapy for severe AD.
Industry analysts, on average, forecast annual sales for dupilumab of $3.0 billion by 2021, according to Thomson Reuters Cortellis.
(Reporting by Ben Hirschler; editing by Jason Neely)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanctions, tight margins sap appetite for rail link to 'Putin's bridge'
- Ford South Africa recalls Kugas after cars burst into flames
- At least five dead, 15 hurt in shooting at Mexico's BPM music festival
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!